Targeted treatment for chronic lymphocytic leukemia

被引：5
|
作者：
Masood, Aisha [2 ]
Sher, Taimur [3 ]
Paulus, Aneel [3 ]
Miller, Kena C. [3 ]
Chitta, Kasyapa S. [4 ]
Chanan-Khan, Asher [1 ]
机构：
[1] Mayo Clin, Div Hematol Oncol, Jacksonville, FL 32224 USA
[2] Mt Sinai Sch Med, Tisch Canc Inst, Bone Marrow Transplant Unit, New York, NY USA
[3] Roswell Pk Canc Inst, Dept Med, New York, NY USA
[4] Roswell Pk Canc Inst, Dept Mol Targets & Expt Therapeut, New York, NY USA
来源：
ONCOTARGETS AND THERAPY | 2011年 / 4卷
关键词：
CLL; Akt inhibitors; Bcl-2; inhibitors; cyclin d kinase inhibitors; heat shock protein inhibitors; immunomodulatory drugs; monoclonal antibodies; NON-HODGKINS-LYMPHOMA; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; PHASE-I; INITIAL THERAPY; MONOCLONAL-ANTIBODY; UNTREATED PATIENTS; CLINICAL-EFFICACY; 1ST-LINE THERAPY; ANTI-CD20; MAB; CELL LYMPHOMA;
D O I：
10.2147/OTT.S7173
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The treatment of chronic lymphocytic leukemia (CLL) has evolved over the last few decades. Recognition has increased of several key components of CLL biology currently manipulated for therapeutics. A milestone in the treatment of CLL was reached with the incorporation of immunotherapy with conventional chemotherapy. The fludarabine/cyclophosphamide/rituximab combination has demonstrated survival advantage for the first time in the treatment of CLL. Several other biological compounds are being explored with the hope of improving responses, impacting survival, and ultimately curing CLL. Important agents being tested are targeted on CLL surface molecules and their ligands, signal transduction protein and oncogenes. This review provides a brief summary of the recent advances made in preclinical and clinical investigation of selected promising therapeutic agents, which lead the target-directed therapeutic approach.
引用
收藏
页码：169 / 183
页数：15
相关论文
共 50 条
  • [1] Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
    Smolej, Lukas
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2015, 8 : 1 - 7
  • [2] Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
    Vitale, Candida
    Gibbons, Jamie Lynn
    Ferrajoli, Alessandra
    ONCOTARGETS AND THERAPY, 2021, 14 : 5507 - 5519
  • [3] The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia
    Jeyakumar, Deepa
    O'Brien, Susan
    ONCOLOGY-NEW YORK, 2016, 30 (11): : 1008 - 1015
  • [4] Targeted therapy for chronic lymphocytic leukemia
    Alfonso Quintás-Cardama
    Susan O’Brien
    Targeted Oncology, 2009, 4 : 11 - 21
  • [5] Targeted Therapy in Chronic Lymphocytic Leukemia
    Kipps, Thomas J.
    Choi, Michael Y.
    CANCER JOURNAL, 2019, 25 (06): : 378 - 385
  • [6] Targeted Agents in Chronic Lymphocytic Leukemia
    O'Brien, Susan M.
    Smith, Ashbel
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (01) : 9 - 11
  • [7] Targeted therapy for chronic lymphocytic leukemia
    Quintas-Cardama, Alfonso
    O'Brien, Susan
    TARGETED ONCOLOGY, 2009, 4 (01) : 11 - 21
  • [8] Unmet Needs in the Treatment of Chronic Lymphocytic Leukemia: Integrating a Targeted Approach
    O'Brien, Susan M.
    Furman, Richard R.
    Byrd, John C.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (01) : 1 - 5
  • [9] Targeted Therapy in Chronic Lymphocytic Leukemia (CLL)
    Pettijohn, Erin M.
    Ma, Shuo
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (01) : 20 - 28
  • [10] Targeted Drug Delivery for Chronic Lymphocytic Leukemia
    Makhloufi Zoulikha
    Wei He
    Pharmaceutical Research, 2022, 39 : 441 - 461
12345